Section Arrow
Quote
MRNS.NASDAQ
- Marinus Pharmaceuticals
Quotes are at least 15-min delayed:2024/05/21 04:39 EDT
Last
 1.35
+0.02 (+1.50%)
Day High 
1.36 
Prev. Close
1.33 
1-M High
1.77 
Volume 
1.31M 
Bid
1.3
Ask
1.34
Day Low
1.27 
Open
1.36 
1-M Low
1.17 
Market Cap 
73.06M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 1.38 
20-SMA 1.41 
50-SMA 5.07 
52-W High 11.26 
52-W Low 1.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.64/-1.18
Enterprise Value
134.48M
Balance Sheet
Book Value Per Share
-0.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
30.99M
Operating Revenue Per Share
0.56
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.16+0.0565+54.59%-- 
NBYNovaBay Pharmaceuticals0.1744+0.0558+47.05%-- 
GTBPGT Biopharma7.8+4.68+150.00%-- 
JAGXJaguar Health0.1686-0.0899-34.78%0.48PE
KTRAKintara Therapeutics0.175+0.032+22.38%-- 
Quotes are at least 15-min delayed：2024/05/21 04:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.